Common checkpoint proteins in immunotherapy include PD-1 (programmed death-1), PD-L1 (programmed death ligand-1) and CTLA-4 (cytotoxic T-lymphocyte associated protein 4), which block the immune cells to attack cancer cells (101, 102). This evidence concerns the gene CTLA4 and cancer.